Send the following on WhatsApp
Continue to ChatOctapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products https://www.vetrinatv.it/octapharma-ag-indirect-comparison-data-indicate-that-personalised-prophylaxis-with-nuwiq-may-lead-to-fewer-patients-with-haemophilia-a-having-bleeds-than-with-other-recombinant-factor-viii-prod/